174
Participants
Start Date
October 12, 2022
Primary Completion Date
May 31, 2026
Study Completion Date
November 30, 2027
Oral MRT-2359
Orally administered tablets of MRT-2359.
Oral MRT-2359
Orally administered tablets of MRT-2359.
Oral MRT-2359
Orally administered tablets of MRT-2359.
Oral MRT-2359
Orally administered tablets of MRT-2359.
Oral MRT-2359
Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
Oral MRT-2359
Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Columbia University Irving Medical Centre, New York
RECRUITING
Virginia Cancer Specialists Research Institute, Fairfax
RECRUITING
Sarah Cannon Research Institute, Lake Mary
RECRUITING
Sarah Cannon Research Institute, Nashville
WITHDRAWN
Indiana University, Bloomington
RECRUITING
Henry Ford Cancer Institute, Detroit
RECRUITING
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
ACTIVE_NOT_RECRUITING
Washington University, St Louis
RECRUITING
University of Kansas Cancer Center, Lawrence
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
South Texas Accelerated Research Therapeutics (START), San Antonio
RECRUITING
South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City
RECRUITING
Honor Health Research Institute, Scottsdale
RECRUITING
University of California San Diego, San Diego
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
Fred Hutchinson Cancer Center, Seattle
ACTIVE_NOT_RECRUITING
Yale University, New Haven
ACTIVE_NOT_RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
MD Anderson Cancer Center, Houston
ACTIVE_NOT_RECRUITING
Cross Cancer Institute, Edmonton
ACTIVE_NOT_RECRUITING
Princess Margaret Hospital, Toronto
Lead Sponsor
Monte Rosa Therapeutics, Inc
INDUSTRY